MarketResearchReports.Biz has announced addition of new report "MIM-D3 (Dry Eye Syndrome) - Forecast and Market Analysis to 2022" to its database.
Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.
Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/177489
Mimetogen Pharmaceutical`s MIM-D3 is under development for the treatment of DES and glaucoma. It is a small-molecule, peptidomimetic of nerve growth factor (NGF), a naturally-occurring protein in the eye that is responsible for the maintenance of the corneal nerves and epithelium, and the production of mucin and tears. While Restasis and many late-stage pipeline products address the inflammatory component of dry eye, MIM-D3 focuses on quickly and efficiently improving the quality of tears produced by the eye. By focusing on this underlying aspect of DES, MIM-D3 also addresses the symptoms of DES, including chronic dryness and grittiness of the ocular surface. Both NGF and brain-derived growth factors have been determined to influence mucin secretion from the conjunctiva, including MUC 5AC. MIM-D3 is a tyrosine kinase receptor agonist that stimulates MUC 5AC secretion from the conjunctival goblet cells.
Explore All Latest Published Reports By GlobalData at http://www.marketresearchreports.biz/publisher/1
Scope
Reasons to buy
About Us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Read our latest articles at http://www.marketresearchreports.biz/articles
Contact Us
Office: State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.
Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/177489
Mimetogen Pharmaceutical`s MIM-D3 is under development for the treatment of DES and glaucoma. It is a small-molecule, peptidomimetic of nerve growth factor (NGF), a naturally-occurring protein in the eye that is responsible for the maintenance of the corneal nerves and epithelium, and the production of mucin and tears. While Restasis and many late-stage pipeline products address the inflammatory component of dry eye, MIM-D3 focuses on quickly and efficiently improving the quality of tears produced by the eye. By focusing on this underlying aspect of DES, MIM-D3 also addresses the symptoms of DES, including chronic dryness and grittiness of the ocular surface. Both NGF and brain-derived growth factors have been determined to influence mucin secretion from the conjunctiva, including MUC 5AC. MIM-D3 is a tyrosine kinase receptor agonist that stimulates MUC 5AC secretion from the conjunctival goblet cells.
Explore All Latest Published Reports By GlobalData at http://www.marketresearchreports.biz/publisher/1
Scope
- Overview of DES, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on MIM-D3 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for MIM-D3 for the top two countries from 2012 to 2022.
- Sales information covered for Japan and China.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for DES
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of MIM-D3 performance
- Obtain sales forecast for MIM-D3 from 2012-2022 in top two countries (Japan and China)
About Us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Read our latest articles at http://www.marketresearchreports.biz/articles
Contact Us
Office: State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz
No comments:
Post a Comment